查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1634627

GLP-1 類似物市場：現況分析與未來預測（2024-2032）

GLP-1 Analogues Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

GLP-1 類似物市場預計將大幅成長，預測期內（2024-2032 年）的複合年增長率為 28%。此外，對減肥解決方案的需求不斷增加以及心血管益處的不斷擴大也在推動市場的發展。新的藥物傳遞方法的出現，特別是口服製劑和長效類似物的開發，也增加了這些藥物的採用。此外，患者對糖尿病認識程度的提高和政府的推廣也改善了市場准入。

2023 年6 月12 日，默克公司（NYSE：MRK，在美國和加拿大以外稱為MSD）將在歐洲肝病研究協會(EASL) 年度會議上提交一份基於臨床試驗的臨床試驗報告會議於 6 月 21 日至 24 日舉行，宣佈有關 GLP-1/胰高血糖素受體共激動劑 efinopentide (MK-6024) 的新發現已被接受進行口頭報告。

根據適應症，市場細分為度拉糖肽（Trulicity）、艾塞那肽（Baydureon、Byetta）、利拉魯肽（Victoza、Saxenda）、索馬魯肽（Ozempic、Wegovy、Ryvelsus）和替澤帕肽（Maunjaro、Zepbound）。 2023年，利拉魯肽（Victoza、Saxenda）將佔較大的市佔率。利拉魯肽是該領域的主要促進因素，因為它是一種多用途 GLP-1，可有效治療第 2 型糖尿病和肥胖症，並具有心血管作用。該產品以 Victoza 和 Saxenda 兩個商品名銷售，分別用於治療糖尿病和治療肥胖症，其多功能性意味著它擁有更廣泛的市場基礎。此外，每家公司都專注於擴大適應症、加強行銷策略以及透過交付系統確保合規性。例如，2024 年6 月24 日，Teva Pharmaceutical Industries Ltd. 的美國子公司Teva Pharmaceuticals, Inc.（紐約證券交易所和特拉維夫證券交易所股票代碼：TEVA）宣佈已獲得VictozaR1（利拉魯肽注射液1.8 毫克）在美國。

根據應用，市場分為第 2 型糖尿病和減肥。 2023年，第2型糖尿病將佔市場的很大佔有率。全球 2 型糖尿病的盛行率不斷上升，需要利拉魯肽等 GLP-1 類似物來幫助控制血糖水平，同時促進減肥。由於此類藥物具有多方面的價值，它們逐漸比傳統藥物更受青睞。此外，公司正在透過擴展到成長領域並與醫療機構合作來鼓勵早期發現，從而改善獲取資訊的機會。

根據分銷管道，市場分為醫院、零售藥局和網路藥局。預計預測期內（2024-2032 年），零售藥局將以顯著的複合年增長率成長。零售藥局在 GLP-1 類似物的分銷中發揮關鍵作用，注重可及性和用戶需求。其覆蓋範圍有助於製造商進入兩個市場，尤其是城市和農村地區，從而提高了需求。他們預計將與零售連鎖店建立持續的關係，並提供培訓和支持計劃，以提高意識並改善對治療計劃的依從性。

為了更瞭解 GLP-1 類似物的市場採用情況，市場分為北美（美國、加拿大和北美其他地區）、歐洲（德國、法國、英國、西班牙、義大利和歐洲其他地區）、亞太地區（分析基於主要地區（中國、日本、印度、亞太其他地區）和其他地區的全球影響力。預計預測期內（2024-2032 年）亞太地區將實現顯著的複合年增長率。背後的原因是糖尿病盛行率不斷上升、城市化發展以及醫療成本不斷上升。此外，人們對正確糖尿病管理意識的不斷增強，推動了中國、印度和日本等主要地區領先的糖尿病管理解決方案的成長。此外，企業也十分重視透過合併、收購、合資、自有生產設施、在地化廣告技術等方式擴大覆蓋範圍。更重要的是，監管部門的批准和低成本產品的供應對於新市場至關重要。此外，所涉及的電子健康技術和遠距醫療正在幫助農村地區的醫療機構接觸和接待入院患者。

市場的主要參與者包括 Novo Nordisk A/S、Lilly、Sanofi、AstraZeneca、Pfizer Inc.、Boehringer Ingelheim International GmbH、Amgen Inc.、ZEALAND PHARMA、Merck &Co.。

目錄

第一章 市場概覽

  • 市場定義
  • 主要目的
  • 利害關係人
  • 限制

第 2 章 研究方法或假設

  • 研究過程
  • 研究方法
  • 受訪者資料

第 3 章執行摘要

  • 產業摘要
  • 各細分市場的展望
    • 市場成長強勁
  • 區域展望

第 4 章 市場動態

  • 驅動程式
  • 機會
  • 阻礙因素
  • 趨勢
  • PESTEL 分析
  • 需求方分析
  • 供給面分析
    • 合併和收購
    • 投資場景
    • 產業洞察：領先的新創公司及其獨特策略

第 5 章 定價分析

  • 按地區進行價格分析
  • 影響價格的因素

6. 2022 年至 2032 年全球 GLP-1 類似物市場收入

第 7 章。
  • 度拉魯肽（Trulicity）
  • 艾塞那肽（Bydureon、Byetta）
  • 利拉魯肽（Victoza、Saxenda）
  • 索馬魯肽（Ozempic、Wegovy、Rybelsus）
  • Tirzepatid（Maunjaro，Zepbound）

第 8 章市場洞察：按應用

  • 2 型糖尿病
  • 減肥

第 9 章。
  • 醫院
  • 零售藥局
  • 網路藥局

第 10 章 市場洞察：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 其他北美地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區

第 11 章 價值鏈分析

  • 邊際分析
  • 市場參與者名單

第 12 章 競爭格局

  • 競爭資訊中心
  • 競爭市場定位分析
  • 波特五力分析

第 13 章 公司簡介

  • Novo Nordisk A/S
    • Company Overview
    • Key Financials
    • SWOT Analysis
    • Product Portfolio
    • Recent Developments
  • Lilly
  • Sanofi
  • AstraZeneca
  • Pfizer Inc.
  • Boehringer Ingelheim International GmbH
  • Amgen Inc.
  • ZEALAND PHARMA
  • Merck & Co., Inc.
  • Hanmi Pharm.Co.,Ltd.

第 14 章 縮寫與先決條件

第 15 章附錄

簡介目錄
Product Code: UMHE213124

GLP-1 (Glucagon-Like Peptide-1) receptors agonists are copies of the naturally occurring GLP-1 hormone that have been modified in some way to make it more effective in treatment. They have an important role in the treatment of type 2 diabetes and obesity as they stimulate the release of insulin, suppress glucagon, decelerate gastric emptying, and increase satiety. These drugs assist in glycemic control and allow for effective weight loss, the two effects being protective of the heart in diabetic patients.

The GLP-1 Analogues Market is expected to grow with a significant CAGR of 28% during the forecast period (2024-2032) due to type 2 diabetes and obesity have risen significantly over the recent past all over the world. Further, increasing the demand for weight loss solutions as well as expanding cardiovascular effectivity scope drive the market. The availability of new methods of drug delivery, especially including oral preparations and the development of long-acting analogues also increases the adoption of the drug. Furthermore, increased patient awareness levels and government promotion related to diabetes improve market access.

On June 12, 2023, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new findings for efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, have been accepted for oral presentation at the European Association for the Study of the Liver (EASL) Annual Congress from June 21-24.

Based on the indication, the market is segmented into Dulaglutide (Trulicity), Exenatide (Bydureon, Byetta), Liraglutide (Victoza, Saxenda), Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound). The Liraglutide (Victoza, Saxenda) held a significant share of the market in 2023. Liraglutide is an area's key driver of growth because it is a miscellaneous GLP-1 that is effective in the treatment of both type 2 diabetes and obesity with cardiovascular effects. The versatility of the product, which goes under the brand name Victoza for diabetes and Saxenda for obesity, means a wider market base. Moreover, companies concentrate on approaches to enlarging indications, enhancing marketing initiatives, and ensuring greater compliance through delivery systems. For instance, on June 24, 2024, Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced the launch of an authorized generic of Victoza(R)1 (liraglutide injection 1.8mg), in the United States.

Based on application, the market is segmented into type 2 diabetes and weight loss. Type 2 diabetes held a significant share of the market in 2023. The increasing global incidence of type 2 diabetes leads to the need for more GLP-1 analogues such as liraglutide that help to manage blood sugar levels while promoting weight loss. Such drugs are progressively preferred with respect to conventional treatments for their multiple valued aspects. Moreover, companies are improving access by expanding into growth lots and partnering with healthcare facilities exerting pressure for early detection.

Based on the distribution channel, the market is segmented into hospitals, retail pharmacies, and online pharmacies. The retail pharmacies are expected to grow with a significant CAGR during the forecast period (2024-2032). Retail pharmacies have an important function in the probabilities of the distribution of GLP-1 analogues, focusing on accessibility and demand by users. Their coverage assists manufacturers in accessing the two markets, especially the urban and the rural areas, making the demand higher. It is required to establish ongoing relations with retail chains, raise awareness and provide training and support programs that would increase compliance with therapy regimens.

For a better understanding of the market adoption of GLP-1 Analogues, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2024-2032). This is because of a growing incidence of diabetes, the growth of cities, and, lastly, the increase in health care costs. Adding to this, the increased concerns among people regarding proper diabetes management drive the growth of superior diabetes management solutions in key areas such as China, India, and Japan. Moreover, companies pay much attention to growing the coverage through mergers, acquisitions, joint ventures, and own production facilities as well as localized advertisement techniques. More importantly, the approval of regulators and the availability of low-cost products are essential for new markets. Further, the concerned e-health technologies and telemedicine are helping the healthcare unit inpatient reach and compliance in rural areas.

Some of the major players operating in the market include Novo Nordisk A/S, Lilly, Sanofi, AstraZeneca, Pfizer Inc., Boehringer Ingelheim International GmbH, Amgen Inc., ZEALAND PHARMA, Merck & Co., Inc., Hanmi Pharm.Co.,Ltd.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the GLP-1 Analogues Market
  • 2.2. Research Methodology of the GLP-1 Analogues Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.GLOBAL GLP-1 ANALOGUES MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY INDICATION

  • 7.1. Dulaglutide (Trulicity)
  • 7.2. Exenatide (Bydureon, Byetta)
  • 7.3. Liraglutide (Victoza, Saxenda)
  • 7.4. Semaglutide (Ozempic, Wegovy, Rybelsus)
  • 7.5. Tirzepatide (Mounjaro, Zepbound)

8.MARKET INSIGHTS BY APPLICATION

  • 8.1. Type 2 Diabetes
  • 8.2. Weight Loss

9.MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 9.1. Hospitals
  • 9.2. Retail Pharmacies
  • 9.3. Online Pharmacies

10.MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. France
    • 10.2.3. UK
    • 10.2.4. Spain
    • 10.2.5. Italy
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of APAC
  • 10.4. Rest of the World

11.VALUE CHAIN ANALYSIS

  • 11.1. Marginal Analysis
  • 11.2. List of Market Participants

12.COMPETITIVE LANDSCAPE

  • 12.1. Competition Dashboard
  • 12.2. Competitor Market Positioning Analysis
  • 12.3. Porter Five Forces Analysis

13.COMPANY PROFILES

  • 13.1. Novo Nordisk A/S
    • 13.1.1. Company Overview
    • 13.1.2. Key Financials
    • 13.1.3. SWOT Analysis
    • 13.1.4. Product Portfolio
    • 13.1.5. Recent Developments
  • 13.2. Lilly
  • 13.3. Sanofi
  • 13.4. AstraZeneca
  • 13.5. Pfizer Inc.
  • 13.6. Boehringer Ingelheim International GmbH
  • 13.7. Amgen Inc.
  • 13.8. ZEALAND PHARMA
  • 13.9. Merck & Co., Inc.
  • 13.10. Hanmi Pharm.Co.,Ltd.

14.ACRONYMS & ASSUMPTION

15.ANNEXURE